• Tyler J Fraum, Kathryn J Fowler, and Jonathan McConathy.
• Mallinckrodt Institute of Radiology, Washington University, Campus Box 8131, 510 S. Kingshighway Blvd., Saint Louis, MO, 63110. Electronic address: fraumt@mir.wustl.edu.
• Acad Radiol. 2016 Feb 1; 23 (2): 220-36.

AbstractPositron emission tomography (PET), commonly performed in conjunction with computed tomography (CT), has revolutionized oncologic imaging. PET/CT has become the standard of care for the initial staging and assessment of treatment response for many different malignancies. Despite this success, PET/CT is often supplemented by magnetic resonance imaging (MRI), which offers superior soft-tissue contrast and a means of assessing cellular density with diffusion-weighted imaging. Consequently, PET/MRI, the newest clinical hybrid imaging modality, has the potential to provide added value over PET/CT or MRI alone. The purpose of this article is to provide a comprehensive review of the current body of literature pertaining to the clinical performance of PET/MRI, with the aim of summarizing current evidence and identifying gaps in knowledge to direct clinical expansion and future research. Multiple example cases are also provided to illustrate the central findings of these publications. Copyright © 2015 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

20 keywords...

hide…